First Tracks Biotherapeutics
TRAX
182 hedge funds and large institutions have $1.28B invested in First Tracks Biotherapeutics in 2026 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 70 increasing their positions, 43 reducing their positions, and 17 closing their positions.
310% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $418K
188% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 17
63% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 43
59% more capital inflows, than outflows
Capital inflows: $302M | Capital outflows: $190M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more funds holding
Funds holding: 150 → 182 (+32)
3.69% more ownership
Funds ownership: 97.7% → 101.38% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$52.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$27.7M |
| 3 |
BlackRock
New York
|
+$24.7M |
| 4 |
Jennison Associates
New York
|
+$19.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
-$32.9M |
| 2 |
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$27.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$25.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$12M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.3M |
TRAX Hedge Fund Activity: Q3 2026 in Review
182 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in First Tracks Biotherapeutics (TRAX) for Q3 2026, worth a combined $1.28B — up 87% from $686M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new TRAX positions and 17 closed out — a net gain of 32 holders — while 70 added to existing stakes and 43 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $52.6M. The largest seller was Vestal Point Capital, cutting an estimated $32.9M.
- 182 institutional investors held First Tracks Biotherapeutics (TRAX) as of Q3 2026, up from 150 in Q2 2026.
- Funds reported $1.28B of First Tracks Biotherapeutics stock for Q3 2026, up 87% quarter-over-quarter.
- 49 funds opened new First Tracks Biotherapeutics positions in Q3 2026 and 17 closed out, a net change of +32 holders.
- The largest First Tracks Biotherapeutics buyer in Q3 2026 was Adage Capital Partners, an estimated $52.6M added.
- The largest First Tracks Biotherapeutics seller in Q3 2026 was Vestal Point Capital, an estimated $32.9M sold.
Based on aggregated 13F filings for Q3 2026.